At our company, we are committed to advancing the field of diagnosing dengue fever, an infectious illness instigated by the dengue virus. Our focus involves developing state-of-the-art antigen and antibody detection reagents/kits alongside diagnostic equipment to tackle the obstacles inherent in diagnosing dengue fever.
Introduction to Dengue Fever
Dengue fever, a viral disease spread by the bite of Aedes mosquitoes carrying the infection, represents a substantial menace to global health. The illness is brought about by one of four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). Upon infection, individuals may remain asymptomatic or develop symptoms ranging from mild flu-like manifestations to severe dengue hemorrhagic fever, characterized by plasma leakage, severe bleeding, and organ impairment.
Fig. 1 Dengue virus infection mechanism. (Yong Y K, et al., 2022)
IVD Development for Dengue Fever
The development of in vitro diagnostic (IVD) tools plays a vital role in the rapid and accurate diagnosis of dengue fever, differentiation of virus serotypes, and monitoring of disease progression. Dengue IVD development relies on the identification of specific diagnostic biomarkers. Effective IVD tools have the potential to elevate the sensitivity, specificity, and efficacy of dengue diagnostic testing.
NS1 Antigen Detection
NS1 antigen is a highly sensitive biomarker for early dengue fever infection. Developing antigen detection kits targeting the dengue virus NS1 protein aids in promptly identifying acute dengue fever cases, enabling timely therapeutic interventions.
Antibody Detection
In dengue fever, IgM antibodies signal acute infection, while IgG antibodies suggest past or secondary infection. Serological tests that detect these antibodies aid in distinguishing between primary and secondary dengue infections.
Point-of-Care Testing (POCT)
Designing rapid POCT devices for decentralized testing in resource-limited settings, enabling immediate diagnosis and therapeutic initiation. POCT can enhance diagnostic services in regions with limited laboratory infrastructure.
IVD Kits for Dengue Fever
IVD kits for dengue fever are continually evolving with advancements in diagnostic technologies and strategies. There are currently multiple dengue IVD kits available on the market, designed to detect specific biomarkers of the dengue virus in samples, aiding in the diagnosis and management of the disease.
NS1 Antigen Detection Kits
These kits use an immunochromatographic assay to detect the presence of the dengue virus NS1 protein, which is usually elevated in the early stages of infection.
Dengue IgM and IgG Antibody Detection Kits
These kits are employed to differentiate between primary and secondary dengue infections by detecting IgM and IgG antibodies produced in response to the virus. ELISA or lateral flow immunoassays are commonly used methods to detect dengue-specific antibodies.
Our Services
We are a leader in infectious disease diagnostic development services, offering groundbreaking IVD solutions for dengue fever to meet complex diagnostic needs. Our expertise lies in designing specialized antigen and antibody detection kits and advanced diagnostic devices tailored specifically for dengue fever, enhancing diagnostic automation and facilitating the effective management of this disease.
IVD Product Development Services
Our services extend beyond these offerings. In our commitment to accelerating swift diagnosis and personalized therapies for dengue fever, we specialize in delivering point-of-care testing (POCT) and companion diagnostic development services. These crucial services significantly improve the efficiency and precision of dengue fever diagnostics, enabling the implementation of personalized care strategies for individuals affected by this condition.
If you are interested in learning more about our services, please do not hesitate to contact us for additional details and pricing information.
Reference
- Yong Y K, Wong W F, Vignesh R, et al. Dengue infection-recent advances in disease pathogenesis in the era of COVID-19[J]. Frontiers in immunology, 2022, 13: 889196.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
